NDA 021225 · Bayer Hlthcare
Mirena
Levonorgestrel · Intrauterine · Progestin; Progestin-containing Intrauterine System
Last checked: Nov 20, 2026Latest source record: Aug 12, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2000
Dec 6, 2000
Approved uses
6
Original approval plus efficacy supplements
Registered trials
354
70 Phase 3, 26 recruiting
FAERS reports
137,670
57,435 serious, 251 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 29, 2025.
Mirena is a progestin-containing intrauterine system (IUS) indicated for: • Prevention of pregnancy for up to 8 years ( 1.1 ) • Treatment of heavy menstrual bleeding for women who choose to use intrauterine contraception as their method of contraception for up to 5 years. ( 1.2 ) 1.1 Contraception Mirena is indicated for prevention of pregnancy for up to 8 years; replace after the end of the eighth year. 1.2 Heavy Menstrual Bleeding Mirena is indicated for the treatment of heavy menstrual bleeding for up to 5 years in women who choose to use intrauterine contraception as their method of contraception; replace after the end of the fifth year if continued treatment of heavy menstrual bleeding is needed.
Mechanism: The local mechanism by which continuously released LNG contributes to the contraceptive effectiveness of Mirena has not been conclusively demonstrated. Studies of Mirena and similar LNG IUS prototypes have suggested several mechanisms that prevent pregnancy: thickening of cervical mucus preventing passage of sperm into the uterus, inhibition of sperm capacitation or survival, and alteration of the endometrium .
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 12, 2022 Supplement 43 · Efficacy LetterLabel
- Aug 11, 2021 Supplement 42 · Efficacy LabelLetter
- Aug 20, 2020 Supplement 40 · Efficacy LabelLetter
- Jun 8, 2017 Supplement 38 · Efficacy LabelLetter
- Oct 1, 2009 Supplement 27 · Efficacy · priority review LetterLabel
- Dec 6, 2000 Original approval · Type 3 - New Dosage Form Pediatric Medical ReviewPediatric Clinical Pharmacology ReviewPediatric Statistical Review
1 products under this application
- MIRENA · LEVONORGESTREL 52MG · SYSTEM, INTRAUTERINE · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Levonorgestrel" as an intervention, any sponsor and status, largest first.
- The Evidence for Contraceptive Options and HIV Outcomes TrialPivotal-lookingCompleted
FHI 360Academic, hospital or other
NCT02550067 · 7,830 participants · Start Dec 14, 2015 · Primary completion Oct 31, 2018
Drug: DMPA; LNG and 1 more · For: HIV; Contraception
Sites: Manzini, Eswatini; Kisumu, Kenya; Brits, South Africa · 12 sites in all
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
NCT00006324 · 6,360 participants · Start Dec 1999
Drug: Ethinyl estradiol/levonorgestrel; Medroxyprogesterone acetate · For: HIV Infections
Sites: Research Triangle Park, North Carolina
- A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of PregnancyPivotal-lookingCompleted
Teva Women's HealthTeva (TEVA)
NCT00996580 · 3,597 participants · Start Oct 2009 · Primary completion Sep 2011
Drug: DR-103 · For: Pregnancy Prevention
Sites: Montgomery, Alabama; Phoenix, Arizona; Tucson, Arizona · 94 sites in all
- Levonorgestrel Contraceptive Intrauterine Systems (LCS) Pearl Index StudyPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00528112 · 2,885 participants · Start Aug 2007 · Primary completion Jul 2011
Drug: LCS12; LCS16 · For: Contraception
Sites: Mobile, Alabama; Glendale, Arizona; Phoenix, Arizona · 136 sites in all
- Open-label Study to Evaluate the Efficacy and Safety of an Extended-cycle, Low Dose Combination Oral ContraceptivePivotal-lookingCompleted
Duramed ResearchIndustry
NCT00196326 · 2,235 participants · Start Jun 2005 · Primary completion Jun 2007
Drug: DR-1011 · For: Contraception
Sites: Huntsville, Alabama; Phoenix, Arizona; Tucson, Arizona · 55 sites in all
- Safety and Efficacy of CDB-2914 in Comparison to Levonorgestrel for Emergency ContraceptionPivotal-lookingCompleted
HRA PharmaIndustry
NCT00551616 · 2,221 participants · Start Apr 2007 · Primary completion Apr 2009
Drug: CDB-2914; Levonorgestrel · For: Contraception
Sites: Los Angeles, California; Santa Monica, California; Boulder, Colorado · 33 sites in all
- Efficacy, Safety and Tolerability Study of Agile AG200-15 Transdermal Contraceptive Delivery SystemPivotal-lookingCompleted
Agile TherapeuticsIndustry
NCT02158572 · 2,032 participants · Start Aug 2014 · Primary completion Nov 2016
Drug: AG200-15 · For: Healthy
- Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring and Levonorgestrel-Ethinyl Estradiol Combined Oral Contraceptive in Adult Women at Risk for Pregnancy (MK-8342B-062)Pivotal-lookingTerminated
Organon and CoIndustry
NCT02616146 · 2,016 participants · Start Dec 1, 2015 · Primary completion Oct 6, 2016
Drug: ENG-E2 125 μg/300 μg vaginal ring; LNG-EE 150 μg/30 μg COC · For: Contraception
Sites: Vienna, Austria; San José, Costa Rica; Glostrup Municipality, Denmark · 14 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- device expulsion37,023
- device dislocation17,421
- genital haemorrhage10,061
- abdominal pain lower7,609
- pain6,843
- vaginal haemorrhage6,790
- uterine perforation6,746
- abdominal pain6,704
- procedural pain6,053
- intra-uterine contraceptive device expelled5,573
- pregnancy with contraceptive device4,955
- complication of device insertion4,811
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 313 |
| 2005 | 505 |
| 2006 | 655 |
| 2007 | 867 |
| 2008 | 10,604 |
| 2009 | 8,233 |
| 2010 | 3,123 |
| 2011 | 16,021 |
| 2012 | 10,282 |
| 2013 | 8,743 |
| 2014 | 8,338 |
| 2015 | 7,366 |
| 2016 | 6,713 |
| 2017 | 8,989 |
| 2018 | 7,599 |
| 2019 | 6,146 |
| 2020 | 6,285 |
| 2021 | 5,461 |
| 2022 | 4,736 |
| 2023 | 4,652 |
| 2024 | 4,847 |
| 2025 | 4,178 |
| 2026 | 3,014 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Mirena (Levonorgestrel)
2024 spending
$758K
Beneficiaries
660
664 claims
Per beneficiary
$1,148
$1,141.29 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $585,899 |
| 2021 | $661,026 |
| 2022 | $697,253 |
| 2023 | $777,252 |
| 2024 | $757,819 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Combined oral contraceptives: venous thrombosis.
de Bastos M, Stegeman BH, Rosendaal FR, et al. · Cochrane Database Syst Rev 2014 · Research Support, Non-U.S. Gov't, Systematic Review
- The norgestrel-T-IUD.
El-Mahgoub S · Contraception 1980 · Clinical Trial, Randomized Controlled Trial
- Fertility-preserving treatment for stage IA endometrial cancer: a systematic review and meta-analysis.
Suzuki Y, Ferris JS, Chen L, et al. · Am J Obstet Gynecol 2024 · Systematic Review, Meta-Analysis
- Do COX-inhibitors improve emergency contraception efficacy?
· Drug Ther Bull 2024 · Randomized Controlled Trial
- Progestin-only pills for contraception.
Grimes DA, Lopez LM, O'Brien PA, et al. · Cochrane Database Syst Rev 2013 · Meta-Analysis, Research Support, N.I.H., Extramural
- Metformin for endometrial hyperplasia.
Shiwani H, Clement NS, Daniels JP, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Meta-Analysis
Sponsor: Bayer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.